Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension

Authors

Stephen L Hauser, University of California, San Francisco
Robert T Naismith, Washington University School of Medicine in St. Louis
et al

Journal

Neurology

Publication Date

9-29-2020

Volume

95

Issue

13

First Page

e1854

Last Page

e1867

Document Type

Open Access Publication

DOI

10.1212/WNL.0000000000010376

Rights and Permissions

Hauser SL, Kappos L, Arnold DL, Bar-Or A, Brochet B, Naismith RT, Traboulsee A, Wolinsky JS, Belachew S, Koendgen H, Levesque V, Manfrini M, Model F, Hubeaux S, Mehta L, Montalban X. Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology. 2020 Sep 29;95(13):e1854-e1867. doi: 10.1212/WNL.0000000000010376 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Recommended Citation

Hauser, Stephen L; Naismith, Robert T; and et al, "Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension." Neurology. 95, 13. e1854 - e1867. (2020).
https://digitalcommons.wustl.edu/open_access_pubs/12003